Breaking Down Yifeng Pharmacy Chain Co., Ltd. Financial Health: Key Insights for Investors

Peeling back the numbers on Yifeng Pharmacy Chain Co., Ltd. (603939.SS) reveals a company with steady sales and solid financial cushions: Q3 2025 revenue stood at ¥5.56 billion, contributing to trailing twelve months (TTM) revenue of ¥24.13 billion (P/S ~1.17) after annual growth of 6.53% in 2024 and stronger prior years, while Q3 net profit attributable was ¥344.51 million (TTM net profit ¥1.64 billion) yielding a net profit margin of 6.35%, EPS (TTM) ¥1.31 and a trailing P/E of 17.05; balance-sheet metrics show total debt of ¥4.70 billion (D/E 0.40) against cash and equivalents of ¥8.11 billion for a net cash position of ¥3.41 billion, book value ¥11.88 billion (BVPS ¥9.22), and an Altman Z‑Score of 3.04, while operating cash flow (LTM) is ¥3.15 billion with free cash flow ¥2.68 billion, ROE 15.59%, gross margin 39.78%, EV/EBITDA 5.71, EV/Sales 1.01, dividend yield 3.58% (payout 72.35%), revenue per employee around ¥602,958 across 40,018 staff, plus growth levers-store expansion, omnichannel integration and digital health-set against regulatory, competitive and supply‑chain risks that investors should weigh.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Revenue Analysis

Yifeng Pharmacy Chain reported steady top-line performance into Q3 2025 but shows signs of slowing momentum compared with prior years. Key headline figures and ratios provide a snapshot of scale, efficiency and valuation versus sales.

• Q3 2025 revenue: ¥5.56 billion (YoY +1.97%).
• Trailing twelve months (TTM) revenue as of 12-Dec-2025: ¥24.13 billion (TTM growth +0.88% YoY).
• Market capitalization: ¥27.06 billion; revenue per share (TTM): ¥19.94.
• Price-to-sales (P/S): ~1.17 based on TTM revenue of ¥24.13 billion; alternate P/S of 1.24 using revenue per share and market cap inputs.
• Revenue per employee (2024): ~¥602,958 with 40,018 employees.

Implications for investors include operational efficiency via revenue per employee, a consistent multi-year topline increase, and a current revenue-growth slowdown that moderates valuation momentum. For further context on ownership and investor interest, see: Exploring Yifeng Pharmacy Chain Co., Ltd. Investor Profile: Who's Buying and Why?

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Profitability Metrics

Key profitability figures for Yifeng Pharmacy Chain Co., Ltd. across the trailing twelve months (TTM) and recent reporting periods highlight steady margin profile, solid returns on equity, and moderate market valuation.

• Q3 2025 net profit attributable to shareholders: ¥344.51 million (YoY +10.14%).
• TTM net profit: ¥1.64 billion.
• TTM net profit margin: 6.35%.
• TTM operating margin: 9.86%.
• Gross margin (TTM): 39.78%.
• EBITDA margin (TTM): 10.99%.
• TTM EPS: ¥1.31; trailing P/E: 17.05.
• Return on equity (ROE): 15.59%.
• Operating profit, first 9 months 2025: ¥1.58 billion (vs. ¥1.40 billion in 1-9M 2024).

Contextual note: the margin set (gross 39.78% → EBITDA 10.99% → operating 9.86% → net 6.35%) shows a typical step-down from product profitability to bottom-line earnings, while ROE of 15.59% and EPS of ¥1.31 with a P/E of 17.05 imply reasonably attractive returns versus price. For related investor insights, see Exploring Yifeng Pharmacy Chain Co., Ltd. Investor Profile: Who's Buying and Why?

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Debt vs. Equity Structure

• Total debt: ¥4.70 billion
• Equity (book value): ¥11.88 billion
• Book value per share: ¥9.22
• Net cash position: ¥3.41 billion (Cash & equivalents ¥8.11 billion less debt)
• Debt-to-equity ratio: 0.40
• Interest coverage ratio: 11.64
• Current ratio: 1.42
• Quick ratio: 0.95

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Liquidity and Solvency

• Operating Cash Flow (LTM): ¥3.15 billion
• Capital Expenditures (LTM): ¥470.99 million
• Free Cash Flow (LTM): ¥2.68 billion
• Free Cash Flow per Share: ¥2.21
• Working Capital: ¥4.48 billion
• Altman Z-Score: 3.04 (low bankruptcy risk)
• Piotroski F-Score: 7 (strong financial/operational quality)
• Cash Flow from Operations: Positive and supportive of reinvestment

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Valuation Analysis

• Valuation posture: Trailing P/E of 17.05 vs forward P/E of 14.50 implies analysts expect earnings improvement; EV/EBITDA of 5.71 signals an earnings-supported valuation.
• Balance-sheet view: P/B of 2.28 shows the market prices Yifeng above net asset value, consistent with brand, store network and intangibles premium.
• Revenue valuation: EV/Sales ~1.01 indicates the market values the firm at roughly one year of revenue - not expensive for a retail pharmacy with stable cash flows.
• Growth-adjusted price: PEG of 1.45 suggests the stock is neither deeply cheap nor richly priced relative to expected EPS growth.
• Income return: Dividend yield 3.58% coupled with a 72.35% payout ratio reflects a shareholder-friendly policy but limited retained earnings for aggressive reinvestment.

• Income investors may be attracted by the 3.58% yield and visible payout commitment, but should monitor payout sustainability given the high 72.35% ratio.
• Value-oriented investors will note EV/EBITDA of 5.71 and EV/Sales ~1.01 as indicators of reasonable entry multiples compared with many retail peers.
• Growth investors should assess whether forecasted earnings justify the PEG of 1.45 and the premium P/B of 2.28.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) Risk Factors

• Regulatory and pricing risk: Changes in drug pricing policies, national centralized procurement and volume-based procurement programs can compress margins quickly. For example, industry-wide procurement initiatives in recent years have driven unit price declines of generic drugs by 20-60% in some categories, directly squeezing retail pharmacy gross margins.
• Competitive pressure: Intense competition from other national chains (e.g., BGI/CJ-like peers), regional chains and fast-growing online platforms (JD Health, AliHealth) can erode market share and force promotional pricing that reduces average selling prices and margins.
• Expansion and leverage risk: Rapid store openings may strain cash flow and increase leverage; aggressive expansion phases historically push up capital expenditures and working capital needs, raising short-term financing requirements and interest expense.
• Supply chain and inventory risk: Disruptions to suppliers, inventory shortages or misalignment with demand patterns can cause stockouts of key categories (chronic meds, vaccines, high-margin OTC), reducing sales and customer retention.
• Macro and consumer demand risk: Economic slowdowns and lower consumer discretionary spending can reduce OTC and wellness product volumes, affecting same-store sales growth and total revenue.
• Policy-driven operational shifts: Required compliance with new traceability, cold-chain or standardized dispensing rules can increase operating costs and necessitate CAPEX or system upgrades.

• Specific financial sensitivities: A 1 percentage-point decline in gross margin on RMB 48bn revenue reduces gross profit by ~RMB 480m, directly impacting operating income given modest operating leverage.
• Cash-flow and refinancing risk: If store rollout continues at historical pace, incremental working capital and build-out spending could push short-term borrowing needs higher; refinancing at higher rates would increase interest burden and compress net margins.
• Inventory turnover sensitivity: Slower turnover (e.g., days inventory outstanding rising from 60 to 80 days) would tie up an additional ~RMB 2.6bn in working capital assuming current COGS levels, pressuring liquidity.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Growth Opportunities

• Store expansion: Yifeng is targeting continued net openings across lower-penetration provinces and selected tier-2/tier-3 cities to increase physical market share.
• Omnichannel integration: investments in online storefronts, mobile apps and in-store pickup aim to convert offline footfall into digital repeat customers.
• Customer loyalty & supply chain: enhanced membership programs and deeper supplier partnerships are being used to increase basket size and improve gross margin.
• Digital health & new services: rollout of chronic disease management, telemedicine links and medical device offerings to diversify revenue beyond OTC/pharmaceutical sales.
• Logistics & tech investments: warehouse automation and route optimization to shorten delivery times and reduce last-mile costs.

• Store rollout economics: targeted breakeven within 12-18 months for standard-format stores when supported by omnichannel sales and local marketing.
• Customer lifetime value (CLTV): expected uplift through loyalty tiers, chronic-disease programs and telehealth cross-sell.
• Margin expansion drivers: private-label growth, centralized procurement, fewer intermediaries and lower logistics cost per order via higher digital mix.
• M&A and partnerships: selective bolt-on acquisitions or alliances with regional chains and health-tech startups to accelerate geographic and service expansion.

• Net new stores per quarter vs. target
• Digital sales % of total revenue and app MAU/DAU
• Same-store sales (SSS) growth
• Gross margin and SG&A as % of revenue
• CapEx on warehouses/IT and payback period